Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

BACKGOUND: Lenalidomide‐based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head‐to‐head comparison, matching‐adjusted indirect comparison (MAIC) was conducted to demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Joshua, Lin, Peggy L., Garcia‐Horton, Viviana, Guyot, Patricia, Singh, Erin, Zhou, Zheng‐Yi, Sievert, Mark, Taiji, Riley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134287/
https://www.ncbi.nlm.nih.gov/pubmed/36726287
http://dx.doi.org/10.1002/cam4.5584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134287/
https://www.ncbi.nlm.nih.gov/pubmed/36726287
http://dx.doi.org/10.1002/cam4.5584

Ejemplares similares